Olaratumab

Drug Profile

Olaratumab

Alternative Names: Anti-PDGFRα mAb 3G3; IMC-3G3; Lartruvo; LY 3012207

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Soft tissue sarcoma
  • Phase I Solid tumours
  • No development reported Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 27 Mar 2017 Eli Lilly plans a phase I/II trial for Pancreatic cancer (Metastatic disease, Late-stage disease, Combination therapy, Second-line therapy) in USA, Germany, Italy and Spain (NCT03086369)
  • 08 Mar 2017 ImClone terminates a phase II trial for Gastrointestinal stromal tumours in USA, Belgium, Germany, Italy, Netherlands, Poland & Spain due to poor accrual (NCT01316263)
  • 11 Jan 2017 Registered for Soft tissue sarcoma (Combination therapy, Late-stage disease) in European Union (IV) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top